Rolling review accelerates the NDA review process, reducing time-to-potential approval. Traders should watch for completion of the NDA submission in H2 2026 and any FDA communication on acceptance or priority review. The stock may re-rate on regulatory progress milestones.
Price Chart
Executive Summary
Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations. The company remains on track to complete the NDA submission in the second half of 2026. This regulatory milestone accelerates the review timeline for a potential first-approved therapy in an indication with no current FDA-approved treatments, a significant catalyst for this clinical-stage biotech.
Key Facts
- FDA granted rolling review for QTORIN™ rapamycin NDA for microcystic lymphatic malformations.
- Palvella remains on track to complete NDA submission in the second half of 2026.
- QTORIN™ rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA.
- No FDA-approved therapies currently exist for the estimated 30,000+ U.S. patients with microcystic LMs.
- Positive Phase 3 SELVA results support the NDA submission.
Financial Impact
First-to-market potential in a rare disease with 30,000+ U.S. patients; no revenue or deal value disclosed.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) after review, including on safety/efficacy or CMC grounds.
- Commercial adoption depends on pricing, reimbursement, and competition from off-label systemic mTOR inhibitors.
- Company is clinical-stage with no approved products and may require additional capital to fund commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access